Pluri Inc. (PLUR), a clinical-stage biotechnology company focused on developing novel cell therapy products, is currently trading at $3.35, marking a 1.33% decline in recent trading sessions. This analysis reviews key technical levels, prevailing market context, and potential price scenarios for the stock, with no investment recommendations included. Key levels to monitor in upcoming sessions include a near-term support floor at $3.18 and a near-term resistance ceiling at $3.52, both of which ha
PLUR Stock Analysis: Pluri Inc. drops 1.33% to $3.35, key support levels assessed
PLUR - Stock Analysis
3160 Comments
1327 Likes
1
Khalanii
Senior Contributor
2 hours ago
This feels deep, I just donโt know how deep.
๐ 183
Reply
2
Naveah
Consistent User
5 hours ago
Who else is trying to stay informed?
๐ 122
Reply
3
Ignazio
Trusted Reader
1 day ago
If only I had checked this sooner.
๐ 297
Reply
4
Jeniah
Influential Reader
1 day ago
Someone call NASA, weโve got a star here. ๐
๐ 192
Reply
5
Mathius
Returning User
2 days ago
Pure genius with a side of charm. ๐
๐ 48
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.